Snowden Capital Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.07M | Buy |
20,107
+7,751
| +63% | +$1.19M | 0.08% | 246 |
|
|
2025
Q4 | $1.7M | Buy |
12,356
+137
| +1% | +$17.9K | 0.04% | 374 |
|
|
2025
Q3 | $1.57M | Sell |
12,219
-259
| -2% | -$31.6K | 0.04% | 387 |
|
|
2025
Q2 | $1.51M | Buy |
12,478
+1,032
| +9% | +$116K | 0.04% | 385 |
|
|
2025
Q1 | $1.32M | Sell |
11,446
-1,653
| -13% | -$176K | 0.04% | 416 |
|
|
2024
Q4 | $1.27M | Sell |
13,099
-733
| -5% | -$78.2K | 0.04% | 426 |
|
|
2024
Q3 | $1.59M | Sell |
13,832
-2,513
| -15% | -$285K | 0.05% | 379 |
|
|
2024
Q2 | $1.74M | Buy |
16,345
+821
| +5% | +$82.4K | 0.05% | 357 |
|
|
2024
Q1 | $1.56M | Buy |
15,524
+462
| +3% | +$47.4K | 0.05% | 384 |
|
|
2023
Q4 | $1.52M | Buy |
15,062
+1,143
| +8% | +$110K | 0.06% | 341 |
|
|
2023
Q3 | $1.42M | Sell |
13,919
-1,372
| -9% | -$139K | 0.06% | 331 |
|
|
2023
Q2 | $1.54M | Sell |
15,291
-1,070
| -7% | -$107K | 0.06% | 350 |
|
|
2023
Q1 | $1.51M | Sell |
16,361
-512
| -3% | -$44.7K | 0.06% | 349 |
|
|
2022
Q4 | $1.53M | Sell |
16,873
-725
| -4% | -$61.1K | 0.06% | 340 |
|
|
2022
Q3 | $1.34M | Sell |
17,598
-4,319
| -20% | -$358K | 0.06% | 347 |
|
|
2022
Q2 | $1.85M | Sell |
21,917
-1,752
| -7% | -$154K | 0.08% | 272 |
|
|
2022
Q1 | $2.08M | Buy |
23,669
+20,307
| +604% | +$1.76M | 0.08% | 272 |
|
|
2021
Q4 | $294K | Sell |
3,362
-24,168
| -88% | -$2.01M | 0.02% | 574 |
|
|
2021
Q3 | $2.25M | Buy |
27,530
+428
| +2% | +$38.5K | 0.11% | 238 |
|
|
2021
Q2 | $2.47M | Buy |
27,102
+14,598
| +117% | +$1.3M | 0.12% | 222 |
|
|
2021
Q1 | $1.07M | Buy |
12,504
+6,607
| +112% | +$593K | 0.06% | 330 |
|
|
2020
Q4 | $557K | Buy |
5,897
+2,874
| +95% | +$251K | 0.04% | 414 |
|
|
2020
Q3 | $263K | Sell |
3,023
-184
| -6% | -$15.9K | 0.02% | 494 |
|
|
2020
Q2 | $280K | Sell |
3,207
-126
| -4% | -$10.9K | 0.02% | 476 |
|
|
2020
Q1 | $275K | Sell |
3,333
-30
| -0.9% | -$2.68K | 0.03% | 447 |
|
|
2019
Q4 | $318K | Sell |
3,363
-2
| -0.1% | -$179 | 0.03% | 474 |
|
|
2019
Q3 | $292K | Sell |
3,365
-324
| -9% | -$29.1K | 0.03% | 431 |
|
|
2019
Q2 | $337K | Sell |
3,689
-439
| -11% | -$37.2K | 0.03% | 393 |
|
|
2019
Q1 | $356K | Buy |
4,128
+250
| +6% | +$20.1K | 0.04% | 379 |
|
|
2018
Q4 | $298K | Buy |
3,878
+913
| +31% | +$71.1K | 0.04% | 382 |
|
|
2018
Q3 | $229K | Buy |
+2,965
| New | +$219K | 0.03% | 445 |
|
Other funds holding NVS
Snowden Capital Advisors's NVS Position: Q1 2026 in Review
Snowden Capital Advisors increased its Novartis (NVS) stake by 63% in Q1 2026, buying an estimated $1.19M and bringing the position to 20,107 shares worth $3.07M. The position accounts for 0.08% of the portfolio, ranked #246.
Snowden Capital Advisors first reported a position in NVS in Q3 2018 and has held it in 31 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Snowden Capital Advisors held 20,107 shares of Novartis worth $3.07M as of Q1 2026.
- Snowden Capital Advisors bought 7,751 Novartis shares in Q1 2026, an estimated $1.19M.
- Novartis made up 0.08% of Snowden Capital Advisors's portfolio in Q1 2026, its #246 holding.
- Snowden Capital Advisors first reported a position in Novartis in Q3 2018 and has held it in 31 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.